Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T M Reilly

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Journal of Cellular Biochemistry|March 21, 2000
Inhibition of neointima formation by a nonpeptide alpha(v)beta(3) integrin receptor antagonist in a rabbit cuff modelA L Racanelli, S K Gibbs, K L Schlingmann, et al.
Circulation|February 1, 1996
Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonistS A Mousa, W F DeGrado, D X Mu, et al.
Thrombosis Research|July 1, 1993
Recombinant plasminogen activator inhibitor-1 protects platelets against the inhibitory effects of plasminT M Reilly, M S Forsythe, A L Racanelli, et al.
Biochemical and Biophysical Research Communications|October 31, 1989
Monoclonal antibodies directed against basic fibroblast growth factor which inhibit its biological activity in vitro and in vivoT M Reilly, D S Taylor, W F Herblin, et al.
Cardiovascular Research|April 16, 1998
Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formationS S Srivatsa, L A Fitzpatrick, P W Tsao, et al.
The Journal of Biological Chemistry|June 5, 1990
Purification and characterization of recombinant plasminogen activator inhibitor-1 from Escherichia coliT M Reilly, R Seetharam, J L Duke, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 11, 1998
Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: comparative platelet binding profiles with c7E3S A Mousa, J M Bozarth, W Lorelli, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 1, 1995
A monoclonal antibody that recognizes the GPIIb/IIIa antagonist DMP 728. Reversal of the effects of DMP 728 on platelet aggregation and bleeding time in the dogT M Reilly, S A Mousa, A L Racanelli, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|October 1, 1992
Effect of thrombin inhibitors on platelet functions: comparative analysis of DuP 714 and hirudinT M Reilly, R M Knabb, S M Hassell, et al.
Biochemical and Biophysical Research Communications|September 30, 1991
Inhibition of the thrombin-platelet reactions by DuP 714A T Chiu, S A Mousa, L J Pease, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Journal of Cellular Biochemistry|March 21, 2000
Inhibition of neointima formation by a nonpeptide alpha(v)beta(3) integrin receptor antagonist in a rabbit cuff modelA L Racanelli, S K Gibbs, K L Schlingmann, et al.
Circulation|February 1, 1996
Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonistS A Mousa, W F DeGrado, D X Mu, et al.
Thrombosis Research|July 1, 1993
Recombinant plasminogen activator inhibitor-1 protects platelets against the inhibitory effects of plasminT M Reilly, M S Forsythe, A L Racanelli, et al.
Biochemical and Biophysical Research Communications|October 31, 1989
Monoclonal antibodies directed against basic fibroblast growth factor which inhibit its biological activity in vitro and in vivoT M Reilly, D S Taylor, W F Herblin, et al.
Cardiovascular Research|April 16, 1998
Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formationS S Srivatsa, L A Fitzpatrick, P W Tsao, et al.
The Journal of Biological Chemistry|June 5, 1990
Purification and characterization of recombinant plasminogen activator inhibitor-1 from Escherichia coliT M Reilly, R Seetharam, J L Duke, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 11, 1998
Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: comparative platelet binding profiles with c7E3S A Mousa, J M Bozarth, W Lorelli, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 1, 1995
A monoclonal antibody that recognizes the GPIIb/IIIa antagonist DMP 728. Reversal of the effects of DMP 728 on platelet aggregation and bleeding time in the dogT M Reilly, S A Mousa, A L Racanelli, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|October 1, 1992
Effect of thrombin inhibitors on platelet functions: comparative analysis of DuP 714 and hirudinT M Reilly, R M Knabb, S M Hassell, et al.
Biochemical and Biophysical Research Communications|September 30, 1991
Inhibition of the thrombin-platelet reactions by DuP 714A T Chiu, S A Mousa, L J Pease, et al.
Pageof 8